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Objective: Osteoarthritis (OA) is the most common rheumatic pathology. It is related to aging and is
characterized primarily by cartilage degradation. Despite its high prevalence, the diagnostic methods
currently available are limited and lack sensitivity. The focus of this review is the application of
proteomic technologies in the search of new biomarkers for improved diagnosis, prognosis and treat-
ment of OA.
Methods: This review focuses on the utilization of proteomics in OA biomarker research to enable early
diagnosis, improved prognosis and the application of tailored treatments.
Results: New diagnostic tests for OA are urgently needed and would also promote the development of
alternative therapeutic strategies. Considering that OA involves different tissues and complex biological
processes, the most promising diagnostic approach would be the study of combinations of biomarkers.
New experimental approaches for the identiﬁcation and validation of OA biomarkers have recently
emerged and include proteomic technologies. These techniques allow the simultaneous analysis of
multiple markers and become a very powerful tool for both biomarker discovery and validation.
Conclusions: Improvements in proteomics technology will undoubtedly lead to advances in character-
izing new OA biomarkers and developing alternative therapies. Even so, further work is required to
enhance the performance and reproducibility of proteomics tools before they can be routinely used in
clinical trials and practice.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most frequent arthropathy. It is char-
acterized by progressive degradation of hyaline articular cartilage
and is associated with aging. Prevalence studies show that OA
usually develops after age 45, its frequency increases with age, and
it affects more than 10% of the population. It is the leading cause of
permanent work incapacity and one of the most common reasons
for visiting primary care physicians. As the population ages, it is
estimated that the number of people with some degree of OA will
double over the next three decades.
A major objective for OA research is the conceptualization and
development of early diagnostic strategies. OA is clinically silent in
most individuals during its initial stages and extensiveo: Francisco J. Blanco, Labo-
Complejo Hospitalario Uni-
4-981-178272; Fax: 34-981-
(F.J. Blanco).
Research Society International. Pudeterioration of cartilage already exists by the time of diagnosis.
Currently, the diagnosis of OA relies on the description of pain
symptoms, stiffness in the affected joints, and radiography, used as
the reference technique for determining the grade of joint
destruction. Limitations in diagnostic tests presently available
provide impetus for the substantial increase in interest in ﬁnding
new speciﬁc biological markers of cartilage degradation, both to
facilitate early diagnosis of joint destruction and to enhance disease
prognosis and evaluation of progression.
In the recent years, new strategies for OA biomarker discovery
and validation have emerged. These include genomic, proteomic
and metabolomic technologies. The current strategy most
employed is transcriptomic analysis using DNA microarrays,
allowing identiﬁcation of candidate genes possibly involved in
cartilage degradation1,2. Gene expression levels, however, do not
necessarily predict protein levels because of alternative transcrip-
tional and translational steps, and the activity of protein degrada-
tion processes. Moreover, genomic studies do not take into account
post-translational modiﬁcations (PTMs) of proteins or their inter-
actions, in many cases essential for biological activities. The
advantage of proteomics is that the actual functional molecules ofblished by Elsevier Ltd. All rights reserved.
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the tissue, not what might be happening. We have recently
reviewed those proteomic analyses performed to increase knowl-
edge about OA pathogenesis3. In this review, we will focus on the
utility of proteomic approaches for OA biomarker research. Pro-
teomic technologies currently available will be discussed, with
particular emphasis on their application to the search of new
diagnostic, prognostic and therapy markers for OA.
Proteomics strategies and technology
Proteomics is a research tool for the large-scale study of protein
structures, functions and interactions. Unlike the genome, the
proteome is highly dynamic, responding to environmental changes,
stress, pathological situations, drug administration, etc. These
factors increase proteome complexity through activation or
suppression of gene expression, alterations in protein interactions,
or changes in PTMs, all affecting protein function.
The basic scheme for proteomics relies on the separation of
a large number of proteins and their identiﬁcation by mass spec-
trometry (MS). Methods and protocols for these techniques are
available in review articles and laboratory handbooks4,5. TheTable I
Proteomic strategies in biomarker research
Strategy Advantages
Shotgun proteomics (survey approach, relative quantiﬁcation)
2-DE, 2D DIGE  High resolution
 Direct detection of PTMs
 Information about Mw and pI of the
Differential labeling and LC–MS/MS
(ICAT, iTRAQ, 18O, SILAC.)
 Medium throughput
 Easy automation
 High resolution with 2D or 3D separ
 Higher quantiﬁcation accuracy than
label-free methods
Label-free LC–MS/MS  Medium throughput
 Easy automation
 High resolution with 2D or 3D separ
 Avoids time and cost-consuming lab
 Unlimited number of experiments ca
be compared
SELDI-TOF-MS  High throughput and automation
Protein arrays  High throughput and automation
 Array format
 Versatility
 High multiplexing power
Targeted proteomics (candidate-based approach)
AQUA  High throughput and automation
 High sensitivity and accuracy
 Allow absolute quantiﬁcation
QconCAT  High sensitivity and accuracy
 Low cost
 Avoids chemical synthesis
 Allow absolute quantiﬁcation
MRM-MS  High sensitivity and accuracy
 High throughput
 High multiplexing power
 Absolute quantiﬁcation
SISCAPA  Enrichment of the target peptides
 High sensitivity and accuracy
 Absolute quantiﬁcation
Protein arrays  High throughput and automation
 Array format
 Versatility
 High multiplexing power
Mw: molecular weight, pI: isoelectric point.
***: highly suitable, **: suitable, *: suitable with limitations.
* Utility of the approach for: BD: biomarker discovery, or BV: biomarker veriﬁcation/vselection of a proteomic approach is mainly dependent on the
technology that the researcher has available (specially, the type and
sensitivity of the mass spectrometer). Each of the strategies that
can be followed for proteomic biomarker discovery or validation
has advantages and disadvantages that are showed in Table I. In
many cases they are not overlapping techniques and provide
complementary information.
Protein separation strategies in proteomics
The separation strategy is a critical step in proteomics. The ﬁrst
proteomic separation methods have been carried out by two-
dimensional electrophoresis (2-DE) of the proteins. These tech-
niques separate proteins by their isoelectric point in the ﬁrst
dimension (using immobilized pH gradient (IPG) strips), and then
by their molecular weight in the second dimension (using
conventional SDS-PAGE gels). The gels are then stained by various
techniques6–8 to visualize the protein spots. Gel images are digi-
tized for analysis, and the proteins selected for identiﬁcation are
picked from the gels and identiﬁed by MS9. Gel-based strategies
have several advantages over other separation techniques, partic-
ularly their high resolution and their capacity for the directDisadvantages Power*
protein
 Low throughput
 Limited dynamic range
 Low-abundant proteins are masked
 Not the technique of choice with
biological ﬂuids
*
BD
ations
 Peptide to protein inference problems
 High labeling costs
 Limited number of experiments to be
compared
**/***
BD
ations
eling step
n
 Peptide to protein inference problems
 Less accurate than labeling-based
MS methods
**/***
BD
 Proteins are not identiﬁed
 Lack of any biological information
**
BD, BV
 Need speciﬁc instrumentation
 Array development
 Sensitivity limited to ﬂuorescence signal
**/***
BD, BV
 Cost of SIL peptides for each protein
 Chemical synthesis of SIL peptides not
always feasible
**
BV
 Time-consuming QconCAT design
and biosynthesis
**
BV
 MRM transitions design may
be complex
 Performed on triple quadrupole
MS instruments
***
BV
 Need of speciﬁc antibodies
 Essential immunoafﬁnity step
**
BV
 Need speciﬁc instrumentation
 Array development
 Sensitivity limited to ﬂuorescence signal
**/***
BD, BV
alidation.
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technique are its poor capacity for high-throughput analysis, the
difﬁculty to separate particular proteins (either very acidic/basic or
very small/large), and that its dynamic range is dependent on gel
staining, which may interfere with protein identiﬁcation.
On the other hand, gel-free or liquid chromatography (LC)
separation methods are currently acquiring greater importance.
Technological advances in this ﬁeld provide the advantages of
being more easily automated, allowing higher throughput and
having increased capacity to detect low-abundant proteins usually
masked by the most abundant proteins in two-dimensional (2D)
gels. Chromatographic separations usually require in-solution
digestion of proteins before analysis; thus, peptides are the
molecules resolved. Like gel-based techniques, chromatographic
processes may involve one or more separation steps10,11. In all
these techniques, protein analysis and identiﬁcation both use MS
data; therefore, these strategies are also known as MS-based
proteomics9.
MS technology and strategies used in proteomics
MS protein identiﬁcation involves a series of steps for protein or
peptide ionization, ion separation, and detection that varies
according to the instrumentation used. Ionization of peptides or
proteins present in the sample may be carried out in solid state
when using instruments with a matrix-assisted laser desorption/
ionization (MALDI) source or in solution for electrospray ionization
(ESI) sources (Fig. 1). Ions are separated according to their mass/
charge relationship (m/z), usually using a time-of-ﬂight (TOF),
quadrupole or ion trap analyzer. Following this step, ion masses are
measured in a detector to provide a mass spectrum reﬂecting the
ion abundancevs itsm/z value used for protein identiﬁcation. Latest
advances in instrumentation, with the introduction of Fourier
transform ion cyclotron resonance (FT-ICR)-MS12 and the most
recently introduced mass analyzer Orbitrap13, provide the advan-
tage of much high resolution, mass accuracy and sensitivity, and are
now being used more frequently for biomarker identiﬁcation.
In proteomics, samples are subjected to multi-dimensional
separation techniques, and individual protein spots or fractions areFig. 1. MS in proteomics. Left, MS instruments employed in proteomics are characterized by
obtained from these instruments. Devices with two or more analyzers are able to provide m
only mass information and allow protein identiﬁcation only by peptide mass ﬁngerprintingdigested with an endoprotease (usually trypsin) to yield peptide
fragments. Then, the peptides are analyzed by MS to establish their
identity, based on their peptide mass ﬁngerprints or further mass
fragmentation to obtain sequence information. Peptide mass
ﬁngerprinting (PMF) identiﬁcation (Fig. 1) is accomplished on
proteins that are previously isolated (either by protein puriﬁcation
or 2-DE), by entering the experimental masses of tryptic peptides
into a database search of predicted protein masses. Protein
sequence identiﬁcation is performed by determination of the
amino acid sequence of a protein14,15.
Quantitative proteomics approaches
Quantiﬁcation of protein levels, in order to achieve accurate
differential protein proﬁling between samples, has been a major
challenge in proteomics16. The best quantitative gel-based tech-
nique to date is differential in-gel electrophoresis (DIGE), in which
protein samples are labeled with ﬂuorescent tags before mixing
them and running them on a 2D gel with a pooled sample used as
the internal standard for quantiﬁcation17. This technique reduces
inter-gel variation and false positives18,19 and results in reliably
reproducible data with biological signiﬁcance. Nevertheless, given
its limitations regarding short dynamic range and poor detection of
low-abundant proteins, gel-based techniques are now considered
inappropriate for biomarker discovery or validation, as these
experiments are usually carried out on plasma or other body ﬂuids
that present a high dynamic range and a number of high abundant
proteins that mask the rest (Table I).
For LC–MS quantiﬁcation, differential labeling of the samples
prior to analysis is usually required (Table I). Several in vitro
chemical or enzymatic labeling methods are used, such as isotope
coded afﬁnity tag (ICAT)20, isobaric tag for relative and absolute
quantitation (iTRAQ)21 or 18O22. Other in vivo metabolic labeling
procedures have been developed and consist of culturing cells in
media with a ‘heavy’ amino acid23,24 15N or 13C25, and comparing
them to cells grown in media containing unlabeled ‘light’ amino
acids. Regardless of the labeling method, quantiﬁcation is achieved
by comparing MS peak intensities of a partner pair of heavy and
light peptides. Recent advances in software applications have alsotheir type of ionization source and their type of mass analyzer/s. Right, MS information
ass and sequence information of the peptides, whereas those with one analyzer give
.
Fig. 2. Types of protein arrays. A: Analytical arrays. B: Functional arrays. Protein arrays
will become the approach of choice for closing the information gap between genomics
and proteomics for the development of new disease biomarkers and therapies.
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electrophoresis or isotope labeling26.
The techniques described thus far provide relative quantiﬁca-
tion information by measuring the relative abundance ratio
between two or more samples. Absolute protein quantiﬁcation
methods in proteomics attempt to measure the absolute protein
level by introducing a characteristic peptide unique to a speciﬁc
protein, providing an explicit external standard of known concen-
tration against which to measure the protein level27. In the AQUA
technique (Table I), peptides are synthesized incorporating stable
isotopes to provide a known mass offset, and these peptides are
used as an internal standard28. Similarly, the quantiﬁcation con-
CATamers (QconCAT) method concatenates stable isotope labeled
(SIL) peptides into a recombinant protein, which is synthesized in
bacterial cell cultures29,30. In many of these analyses, quantiﬁcation
is achieved by multiple reaction monitoring (MRM) MS assays.
These experiments use ESI of the peptides followed by two stages of
mass selection, the ﬁrst one selecting the mass of the intact peptide
(parent ion) and the second one a speciﬁc fragment of the parent
(MRM transitions)31. MRM assays coupled with isotope dilution MS
have proved their utility for quantitative analysis of
biomarkers32,33. Moreover, their reproducibility, recovery, linear
dynamic range, limits of detection (down to ng/ml) and quantiﬁ-
cation of protein biomarkers in plasma have been recently
assessed34. Therefore, MS analysis driven in quantitative MRM
mode is now appearing as a promising alternative to quantify
proteins in biological ﬂuids, avoiding the need of speciﬁc antibodies
and enabling multiplexed analysis (of more than 100 proteins
simultaneously). Finally, the stable isotope standards and capture
by anti-peptide antibodies (SISCAPA) approach35 exploits the use of
immobilized anti-peptide antibodies, used to isolate speciﬁc
peptides together with stable isotopically labeled versions of the
same peptides prior to MRM analysis.
Protein chips
Chip technology is beginning to be applied in proteomics.
Differentially to what happens in genomics, a simple chip for all
proteins is not currently achievable due to the high heterogeneity of
proteins. However, a variety of protein and peptide arrays have
been developed for analyzing a speciﬁc protein or group of
proteins. Surface-enhanced laser desorption ionization (SELDI)
interfaces coupled to a TOF analyzer have made speciﬁc protein
quantiﬁcation in clinical proteomics a reality36–38, and have been
used for clinical and biomedical systems studies, employing
different body ﬂuids to search for biomarkers. Nevertheless, it does
not give any biological information, as the signature peaks are not
identiﬁed.
More recently, other protein microarray platforms are being
developed39. There are currently two general types, analytical
microarrays and functional protein microarrays (Fig. 2)40. Analyt-
ical microarrays are designed for quantitative assessment of
potential biomarkers and other useful proteins. They are most
commonly forward-phase arrays where antibodies or antibody
mimics are immobilized on a solid surface and exposed to a test
sample containing a mixture of proteins. Detection is usually
accomplished using labeled samples or a secondary antibody that
recognizes the antigen of interest (multiple sandwich immunoas-
says). Reverse phase analytical arrays have been developed that are
essentially reciprocals of this technique to proﬁle antibodies in the
plasma or serum41. Also, functional microarray chips to immobilize
puriﬁed peptides or whole proteins on a small surface have been
developed. Unlike antibody microarrays, which are mainly used for
diagnostics and protein expression proﬁling, functional protein
arrays are used for the study of biochemical activities, PTMs, drug-target identiﬁcation, and to analyze protein–protein, DNA–protein,
RNA–protein, and drug–protein interactions.
Proteomics in the search for OA biomarkers
The use of proteomics in biomarker discovery and validation
Proteomics has produced great expectations for the discovery of
biomarkers to improve the diagnosis of a wide range of diseases.
Biomarker research involves a series of steps moving from
discovery to the launch of a commercial biomarker product (Fig. 3).
The technologies of proteomics and metabolomics have a huge
potential for both biomarker discovery and veriﬁcation or valida-
tion. There are two general approaches, target speciﬁc and global/
non-directed, for proteomic biomarker discovery. Target-speciﬁc
approaches frequently use antibodies to screen speciﬁc proteins by
western blot analysis, enzyme-linked immunosorbent assay
(ELISA), or antibody arrays, and are useful for validation and clinical
studies.
However, global/non-directed approaches may have more
potential for biomarker discovery because they are unbiased, high-
throughput screens. There are also two strategies for non-directed
approaches, techniques that proﬁle unidentiﬁed proteins and those
that generate patterns of identiﬁed proteins42. Proﬁling of
unidentiﬁed proteins often, though not always, utilizes MALDI-
TOF-MS or SELDI-TOF-MS. The main advantage of these techniques
is speed in processing many samples, making them attractive tools
for clinical screening. Because peptides of interest are not identiﬁed
in SELDI, validation using other techniques is difﬁcult. However, by
using additional steps after MALDI-TOF analysis, protein peaks of
interest can be identiﬁed. A list of identiﬁed proteins is typically
obtained by tandem MS approaches. Although protein identiﬁca-
tion is now much faster than before human genome sequencing, it
is still slower than the proﬁling-based proteomic procedures
Fig. 3. Steps in biomarker research.
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database searches to identify peaks of interest, but still provide
much information.
Blood (plasma and/or serum), and other body ﬂuids are expec-
ted to be excellent sources of protein biomarkers for proteomic
analyses because they come in contact with most tissues. During
this contact, body ﬂuids pick up proteins secreted or shed by
tissues, a hypothesis that has been recently conﬁrmed43. Although
the major advantage of using plasma and/or serum is that it is
readily obtained, proteins secreted or released from a speciﬁc tissue
or cell type – those that hold the highest potential as biomarkers –
are diluted in blood to a degree that frequently makes them
undetectable by the current available methods. Therefore, great
interest has also been focused on analysis of the so-called
‘‘proximal’’ body ﬂuids, those which contact only one or a few
tissues, thus less dilution of tissue-derived proteins would be
expected. Table I illustrates proteomic strategies for ﬁnding new
biomarker molecules in human body ﬂuids or conditionedmedia in
OA research.Proteomic analysis of plasma and serum
Human plasma has been termed the most complex human
proteome44; its extraordinarily high dynamic range of concentra-
tions of individual proteins challenges current proteomics tech-
nology. Moreover, large variations have been shown to exist
between individuals in the concentration and state of modiﬁcation
of some plasma proteins45, creating a requirement for analyzing
samples from a large number of individuals for statistical accuracy.
Disease biomarkers typically appear at low concentrations in
plasma, making their detection difﬁcult due to the presence of
higher abundance proteins. A practical and effective strategy to
solve this problem is the removal of diagnostically uninformative
high abundance proteins to enhance the detection of low abun-
dance proteins and penetrate deeper into the plasma proteome.
Several systems for plasma protein depletion have been developed
and are commercially available. They consist of antibody-based
resins with afﬁnities to as many as 20 of the most abundant plasma
proteins46, whose removal improves the ability to identify lower
abundance proteins. Disadvantages of this needed depletion step
include reproducibility problems over large samples sets (the half-
life of a depletion column does not exceed 150–200 runs), and thefact that some proteins of interest might be non-speciﬁcally
depleted due to interactions with other proteins such as albumin.
One of the ﬁrst proteomic studies of the serum of OA patients
was based on the hypothesis that immunological pathways may be
implicated in the pathophysiology of OA. The authors developed
a procedure to identify autoantibodies and compared their levels in
sera from OA and rheumatoid arthritis (RA) patients47. In this work,
a 2-DE-based strategy was followed by MALDI-TOF-MS, allowing
recognition of autoantigens by speciﬁc autoantibodies present in
serum (Table II). Anti-triose phosphate isomerase (TPI) protein
autoantibodies were found in OA patients; their presence was
associated with lower radiographic grades of disease. Using the
same methodology, the authors also identiﬁed autoantibodies to
ﬁbulin-4 in the serum of patients with OA48. Currently, SELDI-TOF-
MS is employed for identiﬁcation of new biomarkers speciﬁc for
RA49, using OA samples as a non-inﬂammatory control group.
Proteomic analyses of blood cells from RA patients have also been
performed50,51. Although this approach has not yet been applied in
OA research, it could present a new opportunity.
Finally, using MRM MS and SIL synthetic peptides as internal
standards, C-reactive protein (CRP, a diagnostic marker of RA) was
detected in serum samples taken from patients with either erosive
or non-erosive RA and compared to healthy individuals52. This
exempliﬁes the potential of these targeted proteomics approach for
OA biomarker quantitative studies on serum samples.
Proteomic analysis of synovial ﬂuid (SF)
The speciﬁc features of OA require highly sensitive methods for
biomarker identiﬁcation. The use of SF rather than serum for pro-
teomic techniques to search for biomarkers of OA is advantageous
because it avoids their dilution in other biological ﬂuids. SF is
a logical potential compartment for OA biomarkers because it is
derived directly from the diseased site and functions in the
exchange of proteins between articular cartilage and the systemic
circulation. Consequently, many proteomic strategies in rheuma-
tology are designed to identify putative biomarkers in SF before
their validation in serum.
SF sampling is invasive and samples may need to be clariﬁed by
centrifugation to remove contaminating cells, such as mononuclear
cells, by centrifugation before use in proteomics. It is also
recommended to treat SF samples with hyaluronidase to digest the
hyaluronic acid in order to facilitate proteomics analysis53. Figure 4
Table II
Proteomic approaches in the search for OA biomarkers
Source Goal of the analysis Proteomic strategy Proteins related to disease or treatment References
Body ﬂuids
SF RA vs OA SELDI MRP-8 Uchida et al.60
SF and plasma RA vs OA 2-DE Calgranulin A, Serum amyloid A, Fibrinogen Sinz et al.54
SF OA inter-sample analysis 2-DE Haptoglobin Yamagiwa et al.53
SF and plasma RA vs OA 2-DE MRP-8, MRP-14 Drynda et al.55
Serum RA vs OA, PsA, Asthma, Crohn’s and healthy SELDI MRP-8 de Seny et al.49
Urine OA metabolic proﬁling RMN Metabolite OA proﬁle Lamers et al.67
SF Early and late OA vs control 1-DEþ LC–MS/MS 18 altered in OA Gobezie et al.58
SF OA vs control UFþ LC–MS/MS COL2, PRG4, SAA, TUB, VIME, MGP Kamphorst et al.59
Urine OA vs control Immunoafﬁnity LC–MS/MS uTIINE Nemirovskiy et al.66
Li et al.65
Secreted proteins (conditioned media)
Cartilage OA vs control 2-DEþ LC–MS/MS Activin A, COL2, TIMP Hermansson et al.68
Cartilage OA vs control 2-DEþ off-gelþ antibody arrays PEDF, SAP, OGN, YKL-39, Gelsolin, TIMP-1 De Ceuninck et al.69
Cartilage Effect of cytokines or compression 1-DEþ LC–MS/MS 58 altered by treatment (COMP, COL6, SAA.) Stevens et al.70
Cartilage Effect of IL-1b or RetA 2-DE 20 altered by treatment (COMP, Matrilin-3.) Wilson et al.71
Chondrocytes Effect of IL-1b or TNF-a Antibody array IL-8, IL-6, OPG De Ceuninck et al.72
Chondrocytes Effect of IL-1b or OSM 2-DE MMP-1 and -3, YKL-40, Coﬁlin, Cyclophylin A Catteral et al.73
Chondrocytes Effect of LPS 1-DEþ LC–MS/MS YKL-40, MMP-3 and -13, OGN Haglund et al.74
1-DE: one-dimensional electrophoresis; COL2: type II collagen; COL6: type VI collagen; MGP: matrix Gla protein; MS/MS: tandem mass spectrometry; OGN: osteoglycin;
OPG: osteoprotegerin; OSM: oncostatin M; OSTP: osteopontin; PARC: pulmonary and activation regulated chemokine; PEDF: Pigment epithelium-derived
factor; PRG4: proteoglycan 4; PsA: psoriatic arthritis; RetA: all-trans-retinoic acid; RMN: nuclear magnetic resonance; SAA: serum amyloid A; SAP: serum amyloid P;
UF: ultraﬁltration; uTIINE: urinary type II collagen neoepitope; TUB: tubulin; VIME: Vimentin.
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high quantitative inter-sample variability has been reported for
a number of proteins using 2-DE on samples from OA patients54.
Many proteomic studies performed on SF have focused on RA and
use samples of SF from OA knees for controls (Table II). Differential
analysis of 2-DE protein patterns of SF from OA and RA patients
have enabled the identiﬁcation of molecular markers speciﬁcally
related to RA rather than to OA55, such as calgranulin B and A
amyloid protein. The same authors employed a similar approach to
identify the S100A8/A9 heterocomplex as a marker for discrimi-
nating RA from OA56. LC-based approaches were used to study SF
and serum from RA or OA patients and the results revealed a highFig. 4. Proteomic map of human SF. Separation of SF proteins by 2-DE allows their visualizati
differentiated proteins completes the analysis.number of putative RA biomarkers57. Another study identiﬁed
various possible prognostic RA biomarkers in SF and validated them
in serum53. More recently, two different proteomic approaches
have been developed to gain knowledge of the OA SF protein
proﬁle. One methodology focused on the high abundance pro-
teome58, using one-dimensional (1D) PAGE followed by LC–MS/MS
analysis to identify 18 proteins whose concentrations were
different in OA samples than in controls. Another experiment
studied SF endogenous peptides using ultraﬁltration and LC–MS/
MS analysis59. These authors suggested six proteins that are
potentially useful as markers for the diagnosis of OA (Table II).
Finally, the use of protein biochips with SELDI-MS led to the ﬁndingon and permits a comparative study of OA and normal samples. MS identiﬁcation of the
Table III
Putative OA protein biomarkers described by proteomic strategies
Source Marker* Protein name BIPEDy Ref.
Body ﬂuids
SF and plasma MRP-8,
-14
Myeloid-related proteins
(Calgranulins S100)
I 49,55,60
SAA Serum amyloid A protein I 54,59
FIB Fibrinogen fragments P, E, D 54,58
HPT Haptoglobin I 53
SF COL2 Type II collagen fragments P, E, D 59
PRG4 Proteoglycan 4 P, E, D 59
TUB Tubulin I 59
VIME Vimentin I 59
MGP Matrix gla protein I 59
Urine uTIINE Type II collagen neoepitope B, P, E 65,66
Secreted proteins
Cartilage COL2 Type II collagen fragments P, E, D 68
COL6 Type IV collagen fragments I 70
COMP Cartilage oligomeric matrix
protein
D, B, P 71
INHBA Activin A
(Inhibin beta A chain)
I 68
GELS Gelsolin P, E, D 69
HPT Haptoglobin I 70
MAT3 Matrilin-3 I 71
OGN Osteoglycin (Mimecan) P, E 69,74
SAA Serum amyloid A protein I 70
SAP Serum amyloid P protein I 69
Chondrocytes MMP-1,
-3, -13
Metalloproteinases B, P, E 73,74
OGN Osteoglycin (Mimecan) P, E 69,74
OPG Osteoprotegerin B, P, E 72
TIMP-1 Tissue inhibitor of
Metalloproteinase-1
B, P 69
YKL-39,
-40
Chitinase-like family of
proteins
I 69,73
Abbreviations: B, burden of disease; I, investigative; P, prognostic; E, efﬁcacy of
intervention; D, diagnostic.
* Proteins identiﬁed in the proteomic studies listed and referenced in Table I.
y Hypothetical BIPED classiﬁcation of the markers80.
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for distinguishing between RA and OA60.
Proteomic analysis of other body ﬂuids
Urine, saliva and tears are easily obtained by non-invasive
procedures. Of these, urine is most often used for OA biomarker
investigations. Currently available tests measure the levels of
speciﬁc proteins in urine, and assays for determining the presence
of cartilage degradation markers in urine have been developed.
These include type II collagen C-telopeptide fragments (CTX)61,62
and the collagenase cleavage site neoepitope (TIINE)63. Recently
emerging proteomic technologies now permit the simultaneous
examination of the patterns of multiple urinary proteins and their
correlation to individual diagnoses, responses to treatment or
prognoses (reviewed in Ref. 64). A targeted proteomics approach
has been developed for the quantiﬁcation of urinary TIINE (uTIINE)
using immunoafﬁnity LC–MS/MS65,66, and a metabolomic urinary
proﬁle associated with OA has been identiﬁed67.
Analysis of cartilage or chondrocyte secretomes
The secretome refers to the global array of proteins secreted by
a cell, a tissue or an organism. It is a potential source for the
discovery of biomarker candidates because secreted molecules are
released into the extracellular space and should be detectable in
body ﬂuids. The ﬁrst analysis of the OA cartilage secretome used
2-DE and LC–MS/MS68. These authors found increased type II
collagen synthesis in OA cartilage media and identiﬁed new
potential regulatory molecules of cartilage turnover, such as activin
A. Another study evaluated different technologies for determining
the OA cartilage secretome, including 2-DE, off-gel electrophoresis
and antibody microarrays69. This study identiﬁed 43 proteins
secreted from OA cartilage, some of which were proposed as
potential candidates for biomarkers of diseased cartilage (Table II).
More recently, a study compared secretome proﬁles from bovine
cartilage explants treated with interleukin-1b (IL-1b) or tumor
necrosis factor a (TNF-a) or subjected to traumatic mechanical
compression70. This study found that cytokines stimulate cartilage
cells to release proteins associated with innate immune and stress
responses, whereas the overload compression injury induced the
release of those typical intracellular proteins seen with cartilage
integrity loss, including matrix damage and cell membrane
disruption. The effect of IL-1b and retinoic acid on cartilage secre-
tomes was also evaluated by a 2-DE approach71 from which the
investigators identiﬁed 20 proteins altered by one or both treat-
ments, including matrix metalloproteinase (MMP)-3, cartilage
oligomeric matrix protein (COMP), matrilin-3 or gelsolin.
An alternate approach analyzed the secretome from cultured
chondrocytes. Media from normal and OA chondrocytes treated
with the proinﬂammatory cytokines IL-1b and TNF-a were incu-
bated with array membranes holding 79 antibodies directed
against cytokines, chemokines, and angiogenic and growth
factors72. Using this technique, seven altered proteins were iden-
tiﬁed (Table I), all of which were also found to be secreted by OA
cartilage69. This ﬁnding validates the usefulness of studying the
chondrocyte secretome as a model of events occurring in cartilage
tissue. The secretome of human articular and bovine nasal chon-
drocytes stimulated by IL-1b and oncostatin M was also derived
using 2-DE; proteins regulated differently by these agents were
identiﬁed by ESI-MS/MS73. This work discovered that some of the
secreted proteins were cleaved into smaller fragments by proteol-
ysis. This ﬁnding illustrates the valuable information that proteo-
mics approaches can provide about protein processing, which
cannot be provided by gene-based arrays. Also, a comparativeproteomic analysis using 1D-PAGE and LC–MS/MS was performed
on proteins secreted from lipopolysaccharide (LPS)-stimulated rat
articular chondrocytes in order to study LPS-induced stress
responses of articular cartilage74.Future perspectives
The genome has been the primary focus of past research on the
molecular basis of disease. Proteomics bridges the gap between
what is encoded in the genome and its translation into proteins,
complementing genomics-based approaches and providing addi-
tional information. Recent improvements in proteomics technolo-
gies allowed its application in the clinical ﬁeld, which may lead to
a better understanding of disease biology, the identiﬁcation of
biomarkers and the development of new therapeutic strategies.
New protein array formats and advances in MS equipment have
been major contributions75, although a number of serious chal-
lenges are still being faced, including achieving higher sensitivity
and dynamic range of detection methods and strategies for the
study of PTMs.
An emerging technique for the discovery of protein proﬁles
involves the identiﬁcation of biomarkers by MALDI MS directly on
tissue biopsies76. Traditionally, imaging MS (IMS) had required
substantial effort for sample preparation and data analysis,
rendering it unsuitable for routine clinical use. Recently, IMS
techniques have been optimized77 and a newly described proce-
dure allows imaging of formalin-ﬁxed, parafﬁn-embedded tissue
Fig. 5. Panel A: Chronological appearance of images in the diagnostic process of a rheumatic disease. Panel B: Sequence of the information provided from the different images from
the origin of the disease. Both genomics and proteomics have produced new images to aid physicians in making an early diagnosis and choosing an individually tailored therapy for
patients with OA. The understanding and correct interpretation of these images will become part of daily rheumatology practice in the near future. Interestingly, although these
images have been the last to appear, they provide information about what is happening to patients or populations in the earliest stages of rheumatic diseases. Therefore, these tests
and images will soon be utilized before radiographic imaging in the OA diagnosis process. We will move from managing radiological images from rheumatic diseases to molecular
pictures, obtained either from genomics or proteomics.
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of archived samples in clinical pathology. The ability of MALDI-IMS
to determine the distribution in a certain tissue of hundreds of
unknown compounds in a single measurement makes it a powerful
technique to achieve a better understanding of the underlying
molecular mechanisms of disease. On the other hand, protein
array-based strategies have gained in popularity for clinical sample
evaluation because of their high throughput and automation level.
Protein chips are currently used for large-scale screening of
libraries to identify novel targets or drugs, and probably have the
most potential for analyzing a set of known OA biomarkers.
While these improvements in proteomics technology will
undoubtedly lead to advances in characterizing new OA
biomarkers, further work is required to enhance the performance
and reproducibility of proteomics tools before they can be routinely
used in clinical trials and practice. Up to date, proteomic tools have
a huge power for biomarker discovery (Fig. 3), as they have already
identiﬁed more than a hundred of proteins (or protein fragments)
that might be related with OA (Table II). Some of these, such as
COMP, Coll2 orMMPswere previously detected in other studies and
are currently being validated as OA biomarkers, whereas others
have been characterized only in proteomic analyses, and might be
subjected to further veriﬁcation assays (Table III).
Taking into account its complex pathophysiology, systems
biology approaches to OA – with which researchers try to under-
stand the disease from the level of molecular pathways and the
structure and dynamics of regulatory networks79 – are likely
difﬁcult to achieve. ‘‘Omics’’ strategies provide a huge amount of
experimental data, and efforts are now required to integrate this
information into an understanding of the joint system and its
derangement in OA.When these hurdles are overcome, inclusion of
proteomics in daily diagnosis, prognosis and therapy response
monitoring of OA patients will become a reality (Fig. 5), opening the
gateway for personalized molecular medicine with early stage
diagnosis and tailored therapies designed according to the protein
proﬁle of each individual patient.
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